AstraZeneca PLC (AZN) on Monday said Imfinzi in combination with standard-of-care FLOT chemotherapy has been approved in the European Union for the treatment of adults with resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers.
The FLOT regimen consists of fluorouracil, leucovorin, oxaliplatin and docetaxel. The treatment plan includes two cycles of Imfinzi combined with chemotherapy before and after surgery, followed by Imfinzi monotherapy.
The approval was based on results from the MATTERHORN Phase III trial in which patients treated with the Imfinzi-based perioperative regimen showed statistically significant and clinically meaningful improvements in event-free survival and overall survival.
Imfinzi in combination with FLOT chemotherapy has already been approved in the U.S. and several other countries. Regulatory applications for this indication are currently under review in Japan and other markets.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.